Results 331 to 340 of about 170,525 (342)

Nonalcoholic Steatohepatitis: A Review.

Journal of the American Medical Association (JAMA), 2020
Importance Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) and is associated with disease progression, development of cirrhosis, and need for liver transplant.
A. Sheka, O. Adeyi, Julie Thompson, B. Hameed, P. Crawford, S. Ikramuddin   +5 more
semanticscholar   +1 more source

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

New England Journal of Medicine
BACKGROUND Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death.
Rohit Loomba, M. Hartman, E. Lawitz, R. Vuppalanchi, Jérôme Boursier, E. Bugianesi, Masato Yoneda, C. Behling, O. Cummings, Yuanyuan Tang, B. Brouwers, Deborah A. Robins, A. Nikooie, Mathijs C. Bunck, Axel Haupt, Arun J Sanyal   +15 more
semanticscholar   +1 more source

Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial

Alimentary Pharmacology and Therapeutics
Semaglutide, a glucagon‐like peptide‐1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction‐associated steatohepatitis (MASH).
Philip N. Newsome, Arun J. Sanyal, Kristiane A. Engebretsen, Iris Kliers, L. Østergaard, Denise Vanni, Elisabetta Bugianesi, M. Rinella, M. Roden, V. Ratziu   +9 more
semanticscholar   +1 more source

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

New England Journal of Medicine
BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Arun J. Sanyal, Philip N Newsome, Iris Kliers, L. Østergaard, Michelle T Long, M. Kjær, Anna M G Cali, Elisabetta Bugianesi, M. Rinella, Michael Roden, Vlad Ratziu   +10 more
semanticscholar   +1 more source

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment

Nature reviews: Gastroenterology & hepatology, 2023
J. Llovet, Catherine E. Willoughby, A. Singal, T. Greten, Mathias F Heikenwälder, H. El‐Serag, R. Finn, S. Friedman   +7 more
semanticscholar   +1 more source

Therapeutic pipeline in nonalcoholic steatohepatitis

Nature reviews: Gastroenterology & hepatology, 2021
R. Vuppalanchi, M. Noureddin, N. Alkhouri, A. Sanyal   +3 more
semanticscholar   +1 more source

Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis

New England Journal of Medicine, 2017
A. Diehl, Christopher Day
semanticscholar   +1 more source

The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Nature reviews: Gastroenterology & hepatology, 2018
K. Kazankov, S. M. Jørgensen, K. Thomsen, H. Møller, H. Vilstrup, J. George, D. Schuppan, H. Grønbæk   +7 more
semanticscholar   +1 more source